

DAFTAR PUSTAKA

- Bang, J., Jun, M., Lee, S., Moon, H., & Ro, S. W. (2023). Targeting EGFR/PI3K/AKT/mTOR signaling in hepatocellular carcinoma. *Pharmaceutics*, 15(8), 2130. <https://www.preprints.org/manuscript/202307.1695>
- Chen, S. et al. (2018) ‘Poor prognosis of nucleophosmin overexpression in solid tumors: A meta-analysis’, *BMC Cancer*, 18(1). doi:10.1186/s12885-018-4718-6.
- Henley, S. J., Ward, E. M., Scott, S., Ma, J., Anderson, R. N., Firth, A. U., ... & Kohler, B. A. (2020). Annual report to the nation on the status of cancer, part I: National cancer statistics. *Cancer*, 126(10), 2225-2249.
- International Agency for Research on Cancer. (2024). *GLOBOCAN 2022 (Version 1.1) – World: Statistics at a Glance*. World Health Organization. Retrieved from <https://gco.iarc.who.int/media/globocan/factsheets/populations/900-world-fact-sheet.pdf>
- Kementerian Kesehatan Republik Indonesia. (2022). *Profil Kesehatan Indonesia 2021*. Kementerian Kesehatan Republik Indonesia. <https://www.kemkes.go.id/id/profil-kesehatan-indonesia-2021>. (Accessed: 10 October 2025)
- Kudo, M., Finn, R. S., Qin, S., Han, K. H., Ikeda, K., Piscaglia, F., et al. (2018). Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma (REFLECT): A phase 3, non-inferiority trial. *Lancet*, 391(10126), 1163–1173.
- Llovet, J. M., Montal, R., Sia, D., & Finn, R. S. (2018). Molecular therapies and precision medicine for hepatocellular carcinoma. *Nature reviews Clinical oncology*, 15(10), 599-616.
- Maharani, A.D. et al. (2025) ‘Hepatektomi Pada hepatocellular carcinoma dextra: Laporan Kasus’, *JurnalMU: Jurnal Medis Umum*, 2(1), pp. 23–28. doi:10.30651/jmu.v2i1.25631.
- Mantzanidou, M., Pontiki, E., & Hadjipavlou-Litina, D. (2021). Pyrazoles and Pyrazolines as Anti-Inflammatory Agents. *Molecules*, 26(11), 3439. <https://doi.org/10.3390/molecules26113439>
- Marella, A., Ali, M. R., Alam, M. T., Saha, R., Tanwar, O., Akhter, M., Shaquiquzzaman, M., & Alam, M. M. (2013). Pyrazolines: A biological review. *Mini Reviews in Medicinal Chemistry*, 13(6), 921–931. <https://doi.org/10.2174/1389557511313060012>
- Nawaz, F. et al. (2020) Design, synthesis, molecular docking, and anticancer evaluation of pyrazole linked pyrazoline derivatives with carbothioamide tail as EGFR kinase inhibitors, *Anti-Cancer Agents in Medicinal Chemistry*, 21(1): 42–60. doi:10.2174/1871520620666200727093613.

- Pratama, H., Nurkhasanah, & Suherman, M. (2021). Ekspresi EGFR pada karsinoma hepatoseluler dan implikasinya terhadap terapi target molekuler. *Jurnal Kedokteran Brawijaya*, 34(2), 155–163.
- Sever, R. & Brugge, J.S. (2015) ‘Signal transduction in cancer’, Cold Spring Harbor Perspectives in Medicine, 5(4). <https://doi.org/10.1101/cshperspect.a006098>.
- Siregar, R. A., & Simanjuntak, D. (2022). Tantangan transplantasi hati di Indonesia: Keterbatasan donor dan kebijakan medis. *Jurnal Hepatologi Indonesia*, 10(2), 77–84.
- Sohrab, S.S. & Kamal, M.A. (2022) Screening, Docking, and Molecular Dynamics Study of Natural Compounds as an Anti-HER2 for the Management of Breast Cancer, *Life*, 12(11). <https://doi.org/10.3390/life12111729>.
- Suma, A.A., Wahyuningsih, T.D. and Mustofa, M. (2019) Synthesis, cytotoxicity evaluation and molecular docking study of n-phenylpyrazoline derivatives, *Indonesian Journal of Chemistry*, 19(4): 1081. doi:10.22146/ijc.45777.
- Szumilak, M., Lichota, A., Olczak, A., Szczesio, M., & Stańczak, A. (2019). Molecular insight into quinazoline derivatives with cytotoxic activity. *Journal of Molecular Structure*, 1194, 28-34, doi:10.1016/j.molstruc.2019.05.042.
- Tian, L.-Y., Smit, D.J. and Jücker, M. (2023) The role of PI3K/AKT/mTOR signaling in hepatocellular carcinoma metabolism, *International Journal of Molecular Sciences*, 24(3), p. 2652. doi:10.3390/ijms24032652.
- Torre, A. F., Brizzi, A., & Massa, S. (2018). Pyrazoline derivatives: Synthesis and biological activities. *Current Organic Chemistry*, 22(12), 1234–1256.
- Widiandani, T. et al. (2023) *In vitro* study of pinostrobin propionate and pinostrobin butyrate: Cytotoxic activity against breast cancer cell T47D and its selectivity index, *Journal of Public Health in Africa*, 14(1):6. doi:10.4081/jphia.2023.2516.
- Zamwar, U.M. & Anjankar, A.P. (2022) Aetiology, Epidemiology, Histopathology, Classification, Detailed Evaluation, and Treatment of Ovarian Cancer, *Cureus* [Preprint]. <https://doi.org/10.7759/cureus.30561>.

A;, Ž.E.M.V. (no date) Extended passaging of the skov3 ovarian cancer cell line leads to two phenotypically different strains, Disease models & mechanisms.

Available at: <https://pubmed.ncbi.nlm.nih.gov/40755138/> (Accessed: 15 March 2026).

Bray F;Laversanne M;Sung H;Ferlay J;Siegel RL;Soerjomataram I;Jemal A; (no date) Global cancer statistics 2022: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA: a cancer journal for clinicians. Available at: <https://pubmed.ncbi.nlm.nih.gov/38572751/> (Accessed: 15 March 2026).

Widiandani, T. *et al.* (2023a) 'In vitro study of pinostrobin propionate and pinostrobin butyrate: Cytotoxic activity against breast cancer cell T47D and its selectivity index,' *Journal of Public Health in Africa*, 14(1), p.<https://doi.org/10.4081/jphia.2023.2516>